Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

2
results for

"Jong Joon Lee"

Article category

Keywords

Publication year

"Jong Joon Lee"

Original Articles

Viral hepatitis

The factors associated with longitudinal changes in liver stiffness in patients with chronic hepatitis B
In Ku Yo, Oh Sang Kwon, Jin Woong Park, Jong Joon Lee, Jung Hyun Lee, In Sik Won, Sun Young Na, Pil Kyu Jang, Pyung Hwa Park, Duck Joo Choi, Yun Soo Kim, Ju Hyun Kim
Clin Mol Hepatol 2015;21(1):32-40.
Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.32
Background/Aims

Liver stiffness (LS) as assessed by transient elastography (TE) can change longitudinally in patients with chronic hepatitis B (CHB). The aim of this study was to identify the factors that improve LS.

Methods

Between April 2007 and December 2012, 151 patients with CHB who underwent two TE procedures with an interval of about 2 years were enrolled. Ninety-six of the 151 patients were treated with nucleos(t)ide analogues [the antiviral therapy (+) group], while the remaining 55 patients were not [the antiviral therapy (-) group]. The two groups of patients were stratified according to whether they exhibited an improvement or a deterioration in LS during the study period (defined as an LS change of ≤0 or >0 kPa, respectively, over a 1-year period), and their data were compared.

Results

No differences were observed between the antiviral therapy (+) and (-) groups with respect to either their clinical characteristics or their initial LS. The observed LS improvement was significantly greater in the antiviral therapy (+) group than in the antiviral therapy (-) group (-3.0 vs. 0.98 kPa, P=0.011). In the antiviral therapy (+) group, the initial LS was higher in the LS improvement group (n=63) than in the LS deterioration group (n=33; 7.9 vs. 4.8 kPa, P<0.001). However, there were no differences in any other clinical characteristic. In the antiviral therapy (-) group, the initial LS was also higher in the LS improvement group (n=29) than in the LS deterioration group (n=26; 8.3 vs. 6.5 kPa, P=0.021), with no differences in any other clinical characteristic.

Conclusions

A higher initial LS was the only factor associated with LS improvement in patients with CHB in this study.

Citations

Citations to this article as recorded by  Crossref logo
  • Superior accuracy of a novel multidimensional index integrating static and dynamic liver stiffness for hepatocellular carcinoma risk prediction in chronic hepatitis B
    Yusuke Sano, Naoto Kawabe, Hiroko Sugiyama, Yutaka Sasaki, Keisuke Osakabe, Eizaburo Ohno, Teiji Kuzuya, Senju Hashimoto, Yoshiki Hirooka, Naohiro Ichino
    Journal of Medical Ultrasonics.2026;[Epub]     CrossRef
  • Predictive validation of qualitative fibrosis staging in patients with chronic hepatitis B on antiviral therapy
    Hye Won Lee, Kiyong Na, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Ji Hae Nahm, Jung Il Lee, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Young Nyun Park
    Scientific Reports.2019;[Epub]     CrossRef
  • The Influence of Histologic Inflammation on the Improvement of Liver Stiffness Values Over 1 and 3 Years
    Jeong-Ju Yoo, Yeon Seok Seo, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Sang Jun Suh, Hyung Joon Yim, Ki Tae Suk, Dong Joon Kim, Kwang-Hyub Han, Seung Up Kim, Bora Lee, Sang Gyune Kim
    Journal of Clinical Medicine.2019; 8(12): 2065.     CrossRef
  • Diagnostic Performance of Serum Asialo-α1-acid Glycoprotein for Advanced Liver Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B or Nonalcoholic Fatty Liver Disease
    Seung Up Kim, Mi Young Jeon, Tae Seop Lim
    The Korean Journal of Gastroenterology.2019; 74(6): 341.     CrossRef
  • Reversal of liver cirrhosis: current evidence and expectations
    Young Kul Jung, Hyung Joon Yim
    The Korean Journal of Internal Medicine.2017; 32(2): 213.     CrossRef
  • Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis
    Young Eun Chon, Jun Yong Park, Sung-Min Myoung, Kyu Sik Jung, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han
    American Journal of Gastroenterology.2017; 112(6): 882.     CrossRef
  • Using transient elastography to predict hepatocellular carcinoma recurrence after radiofrequency ablation
    Yu Rim Lee, Soo Young Park, Seung Up Kim, Se Young Jang, Won Young Tak, Young Oh Kweon, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang‐Hyub Han, Keun Hur
    Journal of Gastroenterology and Hepatology.2017; 32(5): 1079.     CrossRef
  • Discordance between conventional ultrasonography and ElastPQ for assessing hepatic fibrosis in chronic hepatitis B: frequency and independent factors
    Mi Sung Kim, Byung Ik Kim, Heon-Ju Kwon, Hae Won Park, Hee-Jin Park, Ki Bae Bang, Hyun Pyo Hong, Myung Ho Rho
    Journal of Medical Ultrasonics.2016; 43(2): 201.     CrossRef
  • Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus
    Ja Yoon Heo, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Young Nyun Park, Sung Soo Ahn, Kwang-Hyub Han, Hyon-Suk Kim
    Medicine.2016; 95(14): e3328.     CrossRef
  • Hepatitis C-A clinical review
    Lan S. Wang, Lionel S. D'Souza, Ira M. Jacobson
    Journal of Medical Virology.2016; 88(11): 1844.     CrossRef
  • Autoimmune Hepatitis-related Cirrhosis
    Yan-Ni Li, Huan Ma, Lu Zhou, Jie Zhang, Li-Ping Guo, Shu-Qian Li, Yi-Qi Qian, Bang-Mao Wang
    Chinese Medical Journal.2016; 129(20): 2434.     CrossRef
  • Improvement of liver function and non‐invasive fibrosis markers in hepatitis B virus‐associated cirrhosis: 2 years of entecavir treatment
    Seung Kak Shin, Jeong Han Kim, Hyeonsu Park, Oh Sang Kwon, Hyun Jung Lee, Jong Eun Yeon, Kwan Soo Byun, Sang Jun Suh, Hyung Joon Yim, Yun Soo Kim, Ju Hyun Kim
    Journal of Gastroenterology and Hepatology.2015; 30(12): 1775.     CrossRef
  • Regression of liver cirrhosis: Orthodoxy or paradigm shift?
    Su Jong Yu
    Clinical and Molecular Hepatology.2015; 21(1): 22.     CrossRef
  • 14,872 View
  • 91 Download
  • 14 Web of Science
  • Crossref
Genetic polymorphism at codon 10 of the transforming growth factor-β1 gene in patients with alcoholic liver cirrhosis
Jong Joon Lee, Soo Kyung Park, Oh Sang Kwon, In Sik Won, Dong Kyu Kim, Young Kul Jung, Yang Suh Ku, Yun Soo Kim, Duck Joo Choi, Ju Hyun Kim
Korean J Hepatol 2011;17(1):37-43.
Published online March 21, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.1.37
Background/Aims

Transforming growth factor beta1 (TGF-β1) is a key cytokine in the production of extracellular matrix. A genetic polymorphism at codon 10 of the TGF-β1 gene is associated with liver fibrosis. We investigated the effect of genetic polymorphisms at codon 10 on the development of alcoholic liver cirrhosis (ALC).

Methods

In total, 119 controls and 182 patients with ALC, were enrolled in the study. Clinical and laboratory data including total lifetime alcohol intake were collected at enrollment. The genotype at codon 10 was determined for each patient by single-strand conformation polymorphism.

Results

There were three types of genetic polymorphism at codon 10: homozygous proline (P/P), heterozygous proline/leucine (P/L), and homozygous leucine (L/L). Among the controls, the proportions of P/P, P/L, and L/L were 26.1%, 44.5%, and 29.4%, respectively in the ALC group, these proportions were 23.1%, 43.4%, and 33.5%, respectively. The genotype distribution did not differ between the controls and the ALC group. In the ALC group, age, total lifetime alcohol intake, and distribution of Child-Pugh class did not differ with the genotype. Of the male patients with ALC (n=164), the proportions of P/P, P/L, and L/L were 20.1%, 44.5%, and 35.4%, respectively the genotype distribution did not differ between the male controls and the male ALC patients.

Conclusions

The genotype at codon 10 in TGF-β1 does not appear to influence the development of ALC. Further study is needed to investigate other genetic factors that influence the development of ALC in patients with chronic alcohol intake.

Citations

Citations to this article as recorded by  Crossref logo
  • Alcoholic Liver Disease: Role of Cytokines
    Manuela Neuman, Yaakov Maor, Radu Nanau, Ehud Melzer, Haim Mell, Mihai Opris, Lawrence Cohen, Stephen Malnick
    Biomolecules.2015; 5(3): 2023.     CrossRef
  • Status of Primary Liver Cancer Found through Routine Health Check-up
    Changhyun Lee, Jong In Yang, Hee Jin Byun, Jung Mook Kang, Seoungho Choi, Jeong Yoon Yim
    Journal of Korean Medical Science.2013; 28(10): 1449.     CrossRef
  • Transforming growth factor-β genetic polymorphisms on development of liver cirrhosis in a meta-analysis
    Xiao-Dan Wu, Kai Zeng, Can-Sheng Gong, Jinhua Chen, Yan-Qing Chen
    Molecular Biology Reports.2013; 40(1): 535.     CrossRef
  • Cellular Mechanisms of Tissue Fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis
    Michael Zeisberg, Raghu Kalluri
    American Journal of Physiology-Cell Physiology.2013; 304(3): C216.     CrossRef
  • 10,526 View
  • 67 Download
  • Crossref